Press release
Stockholm, 16 September 2026

Sobi and Innate announce partnership is now effective following completion of closing conditions

Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the previously announced strategic partnership with Innate is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions.

On the 10th of August 2026, Sobi entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL with first patient expected Q1 2027.

Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma to support a planned accelerated approval filing for Sézary syndrome. The planned TELLOMAK-3 study will support applications for full approvals in key jurisdictions in Sézary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialise lacutamab upon potential accelerated approval and will be eligible to assume full global development rights following positive Phase 3 results.

Under the terms of the agreement, Sobi will pay Innate Pharma USD 75 million upon the partnership becoming effective. Innate will be eligible to receive up to a further USD 40 million in respect of near-term development milestones connected to Sezary syndrome. Additionally, Innate will be eligible to receive up to USD 465 million related to the option for Sobi to get full development rights and to future regulatory and commercial milestones. Innate will be eligible to receive tiered double-digit royalties on net sales.

Sobi®
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Gerard Tobin
Head of Investor Relations

Swedish Orphan Biovitrum AB (publ) (Sobi®)
SE-112 76 Stockholm, Sweden
Visiting address: Norra Stationsgatan 93A, Stockholm, Sweden
+46 8 697 20 00 | info@sobi.com | sobi.com